Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.70 |
| ▸ | HTR2C | P28335 | 19/20 | 0.70 |
| ▸ | HTR2B | P41595 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402850 | 1.00 | HTR2A (0.70) | HTR2AHTR2CHTR2B | |
| SCHEMBL764754 | 0.92 | HTR2C (0.77) | HTR2AHTR2CHTR2B | |
| SCHEMBL764077 | 0.92 | HTR2A (0.65) | HTR2AHTR2CHTR2B | |
| SCHEMBL763734 | 0.89 | HTR2C (0.85) | HTR2AHTR2CHTR2B | |
| SCHEMBL763692 | 0.87 | HTR2A (0.73) | HTR2AHTR2CHTR2B | |
| SCHEMBL8402824 | 0.87 | HTR2A (0.72) | HTR2AHTR2CHTR2B | |
| SCHEMBL765179 | 0.86 | HTR2A (0.68) | HTR2AHTR2CHTR2B | |
| SCHEMBL764623 | 0.86 | HTR2A (0.59) | HTR2AHTR2CHTR2B | |
| SCHEMBL30274486 | 0.85 | HTR2A (0.57) | HTR2AHTR2CHTR2B | |
| SCHEMBL764146 | 0.85 | HTR2A (0.57) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2431369-A2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | VEGFA, FLT4, FLT1 | HTR2A 1527/4885HTR2C 1806/4885HTR2B 2623/4885 |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | HTR2A 2224/4885HTR2C 2368/4885HTR2B 2596/4885 |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | HTR2A 1527/4885HTR2C 1806/4885HTR2B 2623/4885 |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | HTR2A 1837/4885HTR2C 2070/4885HTR2B 2539/4885 |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | VEGFA, FLT4, KDR | HTR2A 2036/4885HTR2C 2345/4885HTR2B 1816/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | HTR2A 824/4885HTR2C 956/4885HTR2B 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.